Related Experiment Video
Updated: Jul 13, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Combination therapy with interferon-beta and glatiramer acetate in multiple sclerosis
C Ytterberg1, S Johansson, M Andersson
1Division of Neurology, Department of Clinical Neuroscience, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden. charlotte.ytterberg@ki.se
Acta Neurologica Scandinavica
|July 31, 2007
Summary
This study compared multiple sclerosis (MS) treatments. Interferon-beta (IFN-beta) plus glatiramer acetate (GA) combination therapy showed a greater change in perceived psychological impact compared to monotherapy.
Area of Science:
- Neurology
- Immunology
- Clinical Research
Background:
- Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Interferon-beta (IFN-beta) and glatiramer acetate (GA) are common disease-modifying therapies for MS.
- Comparing monotherapy with combination therapy is crucial for optimizing MS management.
Purpose of the Study:
- To compare the effectiveness of interferon-beta (IFN-beta) monotherapy, glatiramer acetate (GA) monotherapy, and a combination therapy of IFN-beta + GA in individuals with multiple sclerosis.
- To assess the impact of different treatment regimens on clinical and functional outcomes in MS patients.
Main Methods:
- A longitudinal observational study involving 83 individuals with MS was conducted.
- Participants were categorized into groups receiving IFN-beta monotherapy, GA monotherapy, or switching to IFN-beta + GA combination therapy.
- Outcomes assessed included the Multiple Sclerosis Functional Composite, cognitive function, mood, relapse rates, and perceived physical and psychological impact, analyzed using mixed-effects models and generalized estimating equations.
Main Results:
- The combination therapy of IFN-beta + GA demonstrated a statistically significant greater change in the odds of high perceived psychological impact compared to monotherapy.
- No other significant differences were observed between the combination therapy and monotherapy groups across the assessed outcomes.
Conclusions:
- The findings suggest a potential benefit of IFN-beta + GA combination therapy for psychological well-being in MS patients.
- Further investigation through a randomized controlled trial is warranted to confirm these observations and establish the efficacy of IFN-beta + GA combination therapy in MS.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...